159 related articles for article (PubMed ID: 29334553)
1. Post-treatment controllers after treatment interruption in chronically HIV-infected patients.
Maggiolo F; Di Filippo E; Comi L; Callegaro A
AIDS; 2018 Mar; 32(5):623-628. PubMed ID: 29334553
[TBL] [Abstract][Full Text] [Related]
2. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
Sáez-Cirión A; Bacchus C; Hocqueloux L; Avettand-Fenoel V; Girault I; Lecuroux C; Potard V; Versmisse P; Melard A; Prazuck T; Descours B; Guergnon J; Viard JP; Boufassa F; Lambotte O; Goujard C; Meyer L; Costagliola D; Venet A; Pancino G; Autran B; Rouzioux C;
PLoS Pathog; 2013 Mar; 9(3):e1003211. PubMed ID: 23516360
[TBL] [Abstract][Full Text] [Related]
3. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
4. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
[TBL] [Abstract][Full Text] [Related]
6. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
7. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
[TBL] [Abstract][Full Text] [Related]
10. HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.
Rose R; Lamers SL; Nolan DJ; Maidji E; Faria NR; Pybus OG; Dollar JJ; Maruniak SA; McAvoy AC; Salemi M; Stoddart CA; Singer EJ; McGrath MS
J Virol; 2016 Oct; 90(20):8984-93. PubMed ID: 27466425
[TBL] [Abstract][Full Text] [Related]
11. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
12. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
Lodi S; Meyer L; Kelleher AD; Rosinska M; Ghosn J; Sannes M; Porter K
Arch Intern Med; 2012 Sep; 172(16):1252-5. PubMed ID: 22826124
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
[TBL] [Abstract][Full Text] [Related]
14. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
15. Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.
Cao W; Mehraj V; Trottier B; Baril JG; Leblanc R; Lebouche B; Cox J; Tremblay C; Lu W; Singer J; Li T; Routy JP; ; Vézina S; Charest L; Milne M; Huchet E; Lavoie S; Friedman J; Duchastel M; Villielm F; Côté P; Potter M; Lessard B; Charron MA; Dufresne S; Turgeon ME; Rouleau D; Labrecque L; Fortin C; de Pokomandy A; Hal-Gagné V; Munoz M; Deligne B; Martel-Laferrière V; Gilmore N; Fletcher M; Szabo J
Clin Infect Dis; 2016 Jan; 62(2):250-257. PubMed ID: 26349551
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.
Laanani M; Ghosn J; Essat A; Melard A; Seng R; Gousset M; Panjo H; Mortier E; Girard PM; Goujard C; Meyer L; Rouzioux C;
Clin Infect Dis; 2015 Jun; 60(11):1715-21. PubMed ID: 25737374
[TBL] [Abstract][Full Text] [Related]
17. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
18. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
Wyl Vv; Gianella S; Fischer M; Niederoest B; Kuster H; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
PLoS One; 2011; 6(11):e27463. PubMed ID: 22102898
[TBL] [Abstract][Full Text] [Related]
19. Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.
Uprety P; Chadwick EG; Rainwater-Lovett K; Ziemniak C; Luzuriaga K; Capparelli EV; Yenokyan G; Persaud D
Clin Infect Dis; 2015 Dec; 61(12):1862-70. PubMed ID: 26270687
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
